Zeta Her-2/Neu Antibody. Zeta’s recombinant rabbit antibody recognizes Her-2/Neu (Human epidermal growth factor receptor 2), a transmembrane growth factor receptor that regulates cell growth and survival that is routinely assessed in all primary invasive breast cancer and metastatic/recurrent breast cancer to inform eligibility for anti-HER2 directed targeted therapy. HER-2/Neu is an oncogenic driver with negative prognostic impact in breast cancer. HER-2/Neu testing identifies tumors that may respond to anti-HER2 directed targeted therapy.
The Zeta Her-2/Neu recognizes a protein of 185kDa also known as c-erbB-2 and s a member of the EGFR family. The Her-2/Neu antibody epitope is localized in the extracellular domain. This Her-2/Neu antibody is specific and shows minimal cross-reaction with other members of the EGFR-family. Receptors of the EGFR family are located on the plasma membrane and consist of an extracellular ligand-binding domain connected to a large intracellular domain by a single transmembrane sequence. HER-2/Neu signaling activates multiple major signaling pathways (Ras, Raf, MEK, MAPK and PI3K,AKT) that promote cellular proliferation and antiapoptosis. HER-2/Neu gene amplification results in HER-2/Neu protein overexpression. HER-2/Neu protein is over-expressed in various carcinomas, especially the breast and ovary. HER-2/Neu alteration and dysregulation drives breast cancer progression.
Zeta Corporation is a leader in recombinant monoclonal IVD antibodies for immunohistochemistry (IHC) offering 400+ tumor and tissue specific relevant products developed by a pathologist for pathologists. Visit Precision Recombinant Antibodies – IVD Antibodies – About Zeta Corporation (zeta-corp.com) to learn more about Zeta Corporation.